Veru Stock Price, News & Analysis (NASDAQ:VERU)

$1.32 +0.01 (+0.76 %)
(As of 02/22/2018 04:00 PM ET)
Previous Close$1.31
Today's Range$1.30 - $1.35
52-Week Range$0.90 - $3.00
Volume27,212 shs
Average Volume93,792 shs
Market Capitalization$70.64 million
P/E Ratio-4.89
Dividend YieldN/A
Beta1.2

About Veru (NASDAQ:VERU)

Veru logoVeru Inc., formerly The Female Health Company, is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men's and women's health and oncology. The Company is engaged in the development, manufacture and marketing of consumer healthcare products. The Company has three divisions: Pharmaceutical and Devices, Consumer Health Products and Public Sector. For men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout and sexual dysfunction. Women's Health has product candidates for female sexual health, and advanced breast and ovarian cancers. It manufactures, markets and sells the FC2 Female Condom. FC2 provides dual protection against unintended pregnancy and sexually transmitted infections (STIs), including human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS).

Receive VERU News and Ratings via Email

Sign-up to receive the latest news and ratings for VERU and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryPersonal Products
SectorMedical
SymbolNASDAQ:VERU
CUSIP31446210
Phone305-509-6897

Debt

Debt-to-Equity RatioN/A
Current Ratio1.65%
Quick Ratio1.16%

Price-To-Earnings

Trailing P/E Ratio-4.88870782563609
Forward P/E Ratio-9.43
P/E GrowthN/A

Sales & Book Value

Annual Sales$13.66 million
Price / Sales5.17
Cash FlowN/A
Price / CashN/A
Book Value$0.84 per share
Price / Book1.57

Profitability

Trailing EPS($0.27)
Net Income$-6,610,000.00
Net Margins-73.11%
Return on Equity-17.63%
Return on Assets-12.73%

Miscellaneous

Employees175
Outstanding Shares53,510,000

Veru (NASDAQ:VERU) Frequently Asked Questions

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

How were Veru's earnings last quarter?

Veru Inc (NASDAQ:VERU) released its quarterly earnings data on Wednesday, February, 14th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The company earned $2.59 million during the quarter, compared to the consensus estimate of $5.30 million. Veru had a negative return on equity of 17.63% and a negative net margin of 73.11%. View Veru's Earnings History.

When will Veru make its next earnings announcement?

Veru is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Veru.

Where is Veru's stock going? Where will Veru's stock price be in 2018?

2 brokers have issued 12-month price targets for Veru's stock. Their predictions range from $5.00 to $5.00. On average, they anticipate Veru's share price to reach $5.00 in the next twelve months. View Analyst Ratings for Veru.

Who are some of Veru's key competitors?

Who are Veru's key executives?

Veru's management team includes the folowing people:

  • Elgar Peerschke, Chairman of the Board
  • Mitchell S. Steiner M.D., President, Chief Executive Officer, Director
  • Overton B. Parrish Jr., Vice Chairman of the Board (Age 82)
  • Mario Eisenberger, Director
  • Harry Fisch M.D., Director
  • Lucy Lu M.D., Director (Age 40)
  • Georges Makhoul, Director
  • David R. Bethune, Independent Director (Age 75)

How do I buy Veru stock?

Shares of Veru can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veru's stock price today?

One share of Veru stock can currently be purchased for approximately $1.32.

How big of a company is Veru?

Veru has a market capitalization of $70.64 million and generates $13.66 million in revenue each year. The company earns $-6,610,000.00 in net income (profit) each year or ($0.27) on an earnings per share basis. Veru employs 175 workers across the globe.

How can I contact Veru?

Veru's mailing address is 4400 Biscayne Boulevard Suite 888, Miami FL, 33137. The company can be reached via phone at 305-509-6897 or via email at [email protected]


MarketBeat Community Rating for Veru (VERU)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  89 (Vote Outperform)
Underperform Votes:  43 (Vote Underperform)
Total Votes:  132
MarketBeat's community ratings are surveys of what our community members think about Veru and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Veru (NASDAQ:VERU) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.00$5.00$5.00$5.00
Price Target Upside: 278.79% upside244.83% upside309.84% upside371.70% upside

Veru (NASDAQ:VERU) Consensus Price Target History

Price Target History for Veru (NASDAQ:VERU)

Veru (NASDAQ:VERU) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/15/2018HC WainwrightSet Price TargetBuy$5.00LowView Rating Details
7/26/2017Rodman & RenshawInitiated CoverageBuy -> Buy$5.00HighView Rating Details
(Data available from 2/22/2016 forward)

Earnings

Veru (NASDAQ:VERU) Earnings History and Estimates Chart

Earnings by Quarter for Veru (NASDAQ:VERU)

Veru (NASDAQ VERU) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018        
2/14/2018Q1 2018($0.03)($0.03)$5.30 million$2.59 millionViewListenView Earnings Details
1/2/2018Q4 2017($0.04)($0.10)$3.69 millionViewN/AView Earnings Details
8/8/2017Q3 2017($0.08)($0.03)$2.20 million$4.31 millionViewN/AView Earnings Details
5/9/2017Q2 2017($0.06)$2.41 millionViewListenView Earnings Details
2/9/2017Q1 2017($0.04)$3.24 millionViewN/AView Earnings Details
12/12/2016Q4 2016($0.06)$3.56 millionViewN/AView Earnings Details
7/28/2016Q3$0.02$5.56 millionViewListenView Earnings Details
2/2/2016Q1$0.05$6.66 million$8.23 millionViewN/AView Earnings Details
12/1/2015Q4$0.02$7.16 millionViewN/AView Earnings Details
7/30/2015Q315$0.04$7.28 million$7.81 millionViewListenView Earnings Details
4/30/2015Q215$0.07$0.06$9.48 million$11.00 millionViewN/AView Earnings Details
2/3/2015Q115$0.07$0.03$9.91 million$6.66 millionViewN/AView Earnings Details
12/2/2014Q314$0.02($0.02)$5.55 millionViewN/AView Earnings Details
7/31/2014Q214$0.05$0.04$7.28 million$7.90 millionViewN/AView Earnings Details
5/1/2014Q2 2014$0.02$0.01$4.35 millionViewN/AView Earnings Details
2/3/2014Q114$0.05$0.05$9.91 million$6.69 millionViewN/AView Earnings Details
12/3/2013Q4$0.14$0.23$9.90 million$4.80 millionViewListenView Earnings Details
8/1/2013Q3 2013$0.08$0.03$7.28 millionViewN/AView Earnings Details
5/2/2013Q2 2013$0.12$7.80 million$9.50 millionViewN/AView Earnings Details
1/30/2013Q1 2013$0.12$8.60 million$9.90 millionViewN/AView Earnings Details
12/4/2012Q4 2012$0.11$0.11ViewN/AView Earnings Details
7/31/2012Q3 2012$0.04$0.09ViewN/AView Earnings Details
5/1/2012Q2 2012$0.01$0.07ViewN/AView Earnings Details
1/31/2012Q1 2012$0.01$0.09ViewN/AView Earnings Details
12/2/2011Q4 2011$0.11$0.07ViewN/AView Earnings Details
8/5/2011Q3 2011$0.06$0.01ViewN/AView Earnings Details
2/4/2011Q1 2011$0.01ViewN/AView Earnings Details
12/3/2010Q4 2010$0.03$0.19ViewN/AView Earnings Details
5/7/2010Q2 2010$0.07ViewN/AView Earnings Details
2/8/2010Q1 2010$0.02ViewN/AView Earnings Details
11/30/2009Q4 2009$0.12ViewN/AView Earnings Details
8/7/2009Q3 2009$0.02ViewN/AView Earnings Details
5/8/2009Q2 2009$0.07ViewN/AView Earnings Details
2/10/2009Q1 2009$0.06ViewN/AView Earnings Details
12/1/2008Q4 2008$0.08ViewN/AView Earnings Details
8/12/2008Q3 2008$0.02ViewN/AView Earnings Details
5/14/2008Q2 2008$0.03ViewN/AView Earnings Details
2/13/2008Q1 2008$0.03ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Veru (NASDAQ:VERU) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $-0.08 EPS

Dividends

Veru (NASDAQ:VERU) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/25/2014quarterly$0.073.84%4/28/20144/30/20145/7/2014
3/24/2014quarterly$0.074/30/20144/7/2014
12/16/2013quarterly$0.073.56%1/27/20141/29/20142/5/2014
10/4/2013quarterly$0.072.87%10/28/201310/30/201311/6/2013
7/16/2013quarterly$0.072.99%7/29/20137/31/20138/7/2013
3/27/2013quarterly$0.073.87%4/29/20135/1/20135/8/2013
1/3/2013quarterly$0.063.25%1/28/20131/30/20132/6/2013
(Data available from 1/1/2013 forward)

Insider Trades

Veru (NASDAQ VERU) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 37.00%
Institutional Ownership Percentage: 4.23%
Insider Trades by Quarter for Veru (NASDAQ:VERU)

Veru (NASDAQ VERU) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/15/2017Mitchell Shuster SteinerInsiderBuy100,000$1.63$163,000.007,764,767View SEC Filing  
9/13/2017Harry FischDirectorBuy34,250$1.51$51,717.50View SEC Filing  
8/30/2017Mitchell Shuster SteinerInsiderBuy5,625$1.66$9,337.50View SEC Filing  
8/23/2017Jesus SocorroDirectorBuy7,100$1.44$10,224.007,100View SEC Filing  
6/12/2017Mitchell Shuster SteinerInsiderBuy55,000$1.27$69,850.00645,502View SEC Filing  
6/9/2017Elgar PeerschkeDirectorBuy50,000$1.25$62,500.00145,520View SEC Filing  
6/8/2017Elgar PeerschkeDirectorBuy4,967$1.15$5,712.0593,605View SEC Filing  
6/7/2017Daniel HainesCFOBuy6,000$1.14$6,840.0083,931View SEC Filing  
6/6/2017Elgar PeerschkeDirectorBuy2,852$1.15$3,279.8090,553View SEC Filing  
6/1/2017Daniel HainesCFOBuy10,000$1.10$11,000.0077,931View SEC Filing  
5/30/2017Harry FischDirectorBuy12,000$1.27$15,240.00View SEC Filing  
5/24/2017Harry FischDirectorBuy10,000$1.10$11,000.00View SEC Filing  
5/22/2017Harry FischDirectorBuy24,750$1.02$25,245.00View SEC Filing  
5/17/2017Daniel HainesCFOBuy5,000$1.01$5,050.0067,931View SEC Filing  
5/15/2017Daniel HainesCFOBuy5,000$1.03$5,150.0062,931View SEC Filing  
5/15/2017O B ParrishDirectorBuy20,000$1.02$20,400.00834,849View SEC Filing  
5/12/2017David R BethuneDirectorBuy20,000$1.03$20,600.00415,982View SEC Filing  
5/11/2017Lucy LuDirectorBuy5,000$1.00$5,000.005,000View SEC Filing  
3/20/2017Georges MakhoulDirectorBuy100,000$1.05$105,000.00189,444View SEC Filing  
2/24/2017Daniel HainesCFOBuy7,931$1.03$8,168.9354,000View SEC Filing  
12/15/2016David R BethuneDirectorBuy200$1.06$212.00405,982View SEC Filing  
8/16/2016Andrew S Love JrDirectorBuy20,214$1.39$28,097.46114,626View SEC Filing  
8/15/2016Andrew S Love JrDirectorBuy4,786$1.32$6,317.5293,712View SEC Filing  
6/10/2016Andrew S Love JrDirectorBuy15,000$1.36$20,400.0081,136View SEC Filing  
6/6/2016Andrew S Love JrDirectorBuy1,210$1.40$1,694.0066,136View SEC Filing  
5/24/2016Michele GrecoCFOBuy4,000$1.28$5,120.0067,845View SEC Filing  
5/24/2016O B ParrishCEOBuy10,000$1.29$12,900.00814,849View SEC Filing  
5/23/2016William R Gargiulo JrDirectorBuy500$1.26$630.00102,500View SEC Filing  
5/20/2016David R BethuneDirectorBuy100$1.26$126.00249,115View SEC Filing  
12/18/2015O B ParrishCEOBuy10,000$1.48$14,800.00846,849View SEC Filing  
12/15/2015Andrew S. Love, Jr.DirectorBuy25,000$1.47$36,750.0039,926View SEC Filing  
2/5/2015Karen Louise KingCEOBuy1,000$3.86$3,860.00View SEC Filing  
8/12/2014O B ParrishDirectorBuy5,000$4.05$20,250.00View SEC Filing  
8/6/2014Donna FelchDirectorBuy2,500$3.90$9,750.00View SEC Filing  
8/4/2014Karen Louise KingCEOBuy2,000$3.94$7,880.00View SEC Filing  
5/13/2014Stephen M DearholtDirectorSell203,936$6.05$1,233,812.80View SEC Filing  
3/18/2014William R Gargiulo JrDirectorBuy1,000$6.81$6,810.00View SEC Filing  
3/17/2014O B ParrishDirectorBuy5,000$6.74$33,700.00View SEC Filing  
12/20/2013Stephen M DearholtDirectorBuy2,000$8.27$16,540.00View SEC Filing  
12/18/2013David R BethuneDirectorBuy4,000$8.07$32,280.00View SEC Filing  
3/8/2013Michele GrecoCFOBuy1,000$7.01$7,010.00View SEC Filing  
9/17/2012Stephen M DearholtDirectorSell25,000$7.02$175,500.00View SEC Filing  
8/9/2012Michael PopeVPSell17,056$5.90$100,630.40View SEC Filing  
8/8/2012Richard E WenningerDirectorSell3,260$6.00$19,560.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Veru (NASDAQ VERU) News Headlines

Source:
DateHeadline
Veru (VERU) Earns Buy Rating from HC WainwrightVeru (VERU) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - February 15 at 9:58 AM
Verus (VERU) CEO Dr. Mitchell Steiner on Q1 2018 Results - Earnings Call TranscriptVeru's (VERU) CEO Dr. Mitchell Steiner on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - February 15 at 7:24 AM
Veru (VERU) Releases  Earnings Results, Misses Expectations By $0.05 EPSVeru (VERU) Releases Earnings Results, Misses Expectations By $0.05 EPS
www.americanbankingnews.com - February 14 at 3:16 PM
Veru Reports Fiscal 2018 First-Quarter Financial ResultsVeru Reports Fiscal 2018 First-Quarter Financial Results
finance.yahoo.com - February 14 at 7:27 AM
Veru Inc to Host Earnings CallVeru Inc to Host Earnings Call
finance.yahoo.com - February 14 at 7:27 AM
Veru (VERU) Scheduled to Post Earnings on WednesdayVeru (VERU) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - February 9 at 12:16 AM
Veru to Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call on February 14Veru to Report Fiscal 2018 First-Quarter Financial Results, Host Conference Call on February 14
finance.yahoo.com - February 8 at 7:12 AM
Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate ... - GlobeNewswire (press release)Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate ... - GlobeNewswire (press release)
globenewswire.com - February 7 at 7:15 AM
BRIEF-Veru to Present At 2018 Genitourinary Cancers SymposiumBRIEF-Veru to Present At 2018 Genitourinary Cancers Symposium
www.reuters.com - February 6 at 3:28 PM
Veru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Genitourinary Cancers SymposiumVeru Announces Presentation of Data Demonstrating Efficacy of VERU-111 in a Taxane Resistant Human Prostate Cancer Model at the 2018 Genitourinary Cancers Symposium
finance.yahoo.com - February 6 at 3:28 PM
Contrasting Veru (VERU) & BioDelivery Sciences International (BDSI)Contrasting Veru (VERU) & BioDelivery Sciences International (BDSI)
www.americanbankingnews.com - February 6 at 1:28 PM
United States Sexual Wellness (Condoms, Vibrators, Lubricants ... - PR Newswire (press release)United States Sexual Wellness (Condoms, Vibrators, Lubricants ... - PR Newswire (press release)
www.prnewswire.com - January 24 at 3:33 PM
United States Sexual Wellness (Condoms, Vibrators, Lubricants) Market Analysis & Segment Forecasts 2014-2017 ... - GlobeNewswire (press release)United States Sexual Wellness (Condoms, Vibrators, Lubricants) Market Analysis & Segment Forecasts 2014-2017 ... - GlobeNewswire (press release)
globenewswire.com - January 24 at 5:31 AM
The U.S. sexual wellness market is expected to reach USD 8.8 billion by 2025The U.S. sexual wellness market is expected to reach USD 8.8 billion by 2025
www.bizjournals.com - January 22 at 3:36 PM
Free Research Report as Veru’s Revenue Grew 3.6%Free Research Report as Veru’s Revenue Grew 3.6%
finance.yahoo.com - January 16 at 9:00 AM
Zacks: Analysts Set $5.00 Target Price for Veru Inc (VERU)Zacks: Analysts Set $5.00 Target Price for Veru Inc (VERU)
www.americanbankingnews.com - January 15 at 3:32 AM
Veru (VERU) Lowered to "Strong Sell" at Zacks Investment ResearchVeru (VERU) Lowered to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - January 6 at 10:20 AM
Health Care Sector Update for 01/02/2018: VERU, BTX, SNGX ... - NasdaqHealth Care Sector Update for 01/02/2018: VERU, BTX, SNGX ... - Nasdaq
www.nasdaq.com - January 3 at 8:06 AM
BRIEF-Veru Inc Files For Non-Timely 10-KBRIEF-Veru Inc Files For Non-Timely 10-K
www.reuters.com - January 2 at 7:35 PM
Veru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial Results - GlobeNewswire (press release)Veru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial Results - GlobeNewswire (press release)
globenewswire.com - January 2 at 8:53 AM
Veru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial ResultsVeru Reports Fiscal 2017 Fourth-Quarter, Full-Year Financial Results
finance.yahoo.com - January 2 at 8:53 AM
 Veru Inc (VERU) Given $5.00 Average Price Target by Analysts Veru Inc (VERU) Given $5.00 Average Price Target by Analysts
www.americanbankingnews.com - December 17 at 5:32 PM
Veru (VERU) Given a $5.00 Price Target at HC WainwrightVeru (VERU) Given a $5.00 Price Target at HC Wainwright
www.americanbankingnews.com - December 14 at 7:46 PM
ETFs with exposure to Veru, Inc. : December 14, 2017ETFs with exposure to Veru, Inc. : December 14, 2017
finance.yahoo.com - December 14 at 6:25 PM
Veru Acquires Novel Proprietary Formulation for Overactive BladderVeru Acquires Novel Proprietary Formulation for Overactive Bladder
finance.yahoo.com - December 11 at 9:31 AM
At $1.1572, Is Veru Inc (VERU) A Buy?At $1.1572, Is Veru Inc (VERU) A Buy?
finance.yahoo.com - November 28 at 11:25 AM
Female Health Company (The) (VERU) Given a $5.00 Price Target by HC Wainwright AnalystsFemale Health Company (The) (VERU) Given a $5.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - November 25 at 12:56 PM
Ubers $100,000 cyberattack cover-up is just the latest in a long list of scandalsUber's $100,000 cyberattack cover-up is just the latest in a long list of scandals
www.businessinsider.com - November 24 at 8:29 AM
The Anti-GMO Movement Has A Social Justice ProblemThe Anti-GMO Movement Has A Social Justice Problem
www.forbes.com - November 20 at 3:51 PM
Female Health Company (The) (VERU) Downgraded by ValuEngineFemale Health Company (The) (VERU) Downgraded by ValuEngine
www.americanbankingnews.com - November 18 at 12:04 AM
Veru Announces Tamsulosin DRS Bioequivalence Clinical Trial ResultsVeru Announces Tamsulosin DRS Bioequivalence Clinical Trial Results
finance.yahoo.com - November 13 at 11:21 AM
Reviewing Taro Pharmaceutical Industries (TARO) & Female Health Company (The) (VERU)Reviewing Taro Pharmaceutical Industries (TARO) & Female Health Company (The) (VERU)
www.americanbankingnews.com - November 11 at 9:26 PM
Progenity Announces Closing of $125 Million Financing for Prenatal-Women’s Health Genetics and Gastrointestinal/Inflammatory Bowel Disease Precision MedicineProgenity Announces Closing of $125 Million Financing for Prenatal-Women’s Health Genetics and Gastrointestinal/Inflammatory Bowel Disease Precision Medicine
www.businesswire.com - November 7 at 1:03 PM
11 women who prove that health tech investing isnt a boys club11 women who prove that health tech investing isn't a boys' club
www.cnbc.com - October 30 at 8:17 AM
Critical Review: Female Health Company (The) (VERU) and The CompetitionCritical Review: Female Health Company (The) (VERU) and The Competition
www.americanbankingnews.com - October 28 at 1:28 PM
Why Flexible Workplaces Are A Win/Win For Women EntrepreneursWhy Flexible Workplaces Are A Win/Win For Women Entrepreneurs
www.forbes.com - October 27 at 7:33 AM
How to snuff out the grotesque epidemic of sexual harassment? Start earlyHow to snuff out the grotesque epidemic of sexual harassment? Start early
www.latimes.com - October 27 at 7:33 AM
Head-To-Head Review: Female Health Company (The) (VERU) vs. Its RivalsHead-To-Head Review: Female Health Company (The) (VERU) vs. Its Rivals
www.americanbankingnews.com - October 26 at 11:36 AM
When Women Rule: Corporate woman turns village head to bring roads, water and banking to rural IndiansWhen Women Rule: Corporate woman turns village head to bring roads, water and banking to rural Indians
www.reuters.com - October 25 at 3:57 PM
Neothetics, Inc. And Evofem Biosciences, Inc. Announce Merger Agreement To Create Womens Health CompanyNeothetics, Inc. And Evofem Biosciences, Inc. Announce Merger Agreement To Create Women's Health Company
www.thestreet.com - October 17 at 8:47 AM
Harvey Weinstein is a symptom, but what is the deeper problem?Harvey Weinstein is a symptom, but what is the deeper problem?
www.cnn.com - October 11 at 4:35 PM
Soldier Dances, From a Land Pervaded by the MilitarySoldier Dances, From a Land Pervaded by the Military
www.nytimes.com - October 11 at 4:35 PM
HC Wainwright Reiterates "Buy" Rating for Female Health Company (The) (VERU)HC Wainwright Reiterates "Buy" Rating for Female Health Company (The) (VERU)
www.americanbankingnews.com - October 8 at 6:02 PM
Contrasting Female Health Company (The) (VERU) and Its CompetitorsContrasting Female Health Company (The) (VERU) and Its Competitors
www.americanbankingnews.com - October 5 at 12:16 AM
Veru Inc. Announces Initiation of Telemedicine Capability to Expand Access to Prescriptions for FC2 Female CondomVeru Inc. Announces Initiation of Telemedicine Capability to Expand Access to Prescriptions for FC2 Female Condom
finance.yahoo.com - October 3 at 2:30 PM
ETFs with exposure to Veru, Inc. : September 28, 2017ETFs with exposure to Veru, Inc. : September 28, 2017
finance.yahoo.com - October 3 at 2:30 PM
Veru Inc. Announces Agreement with Timm Medical Technologies, LLC to Distribute and to Promote PREBOOSTVeru Inc. Announces Agreement with Timm Medical Technologies, LLC to Distribute and to Promote PREBOOST
finance.yahoo.com - October 3 at 2:30 PM
Female Health Company (The) (VERU) and Its Rivals Financial ContrastFemale Health Company (The) (VERU) and Its Rivals Financial Contrast
www.americanbankingnews.com - October 3 at 12:30 PM
Innoviva (INVA) vs. Female Health Company (The) (VERU) Head-To-Head ComparisonInnoviva (INVA) vs. Female Health Company (The) (VERU) Head-To-Head Comparison
www.americanbankingnews.com - September 28 at 6:32 PM
Veru Inc. to Present at Two Financial Conferences in SeptemberVeru Inc. to Present at Two Financial Conferences in September
finance.yahoo.com - September 20 at 10:52 AM

SEC Filings

Veru (NASDAQ:VERU) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Veru (NASDAQ:VERU) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Veru (NASDAQ VERU) Stock Chart for Thursday, February, 22, 2018

Loading chart…

This page was last updated on 2/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.